Items where Author is "Sabzvari, A."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 8.

(2025) Evaluation of efficacy and safety of generic tacrolimus (Suprotac((R))) compared to reference tacrolimus (Prograf((R))) in kidney transplantation: a phase IV study. European journal of translational myology. ISSN 2037-7452 (Print) 2037-7452 (Linking)

(2025) Safety and effectiveness of a biosimilar somatropin (Cinnatropin®) in children and adolescents receiving growth hormone therapy over 1 year: a registry-based phase IV study. European Journal of Pediatrics. p. 9. ISSN 0340-6199

(2025) A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta® (reference product) in previously treated patients with severe haemophilia A. Annals of Hematology. pp. 1195-1202. ISSN 0939-5555

(2024) Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial. Frontiers in Immunology. p. 10. ISSN 1664-3224

(2024) Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY). Multiple Sclerosis and Related Disorders. p. 8. ISSN 2211-0348

(2024) Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial. Scientific Reports. p. 12. ISSN 2045-2322

(2024) Evaluating the Efficacy and Safety of Aflibercept Biosimilar (P041) Compared with Originator Product in Patients with Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. pp. 744-753. ISSN 2468-6530

(2021) A Phase IV Study of the Safety and Efficacy of CinnoPar (R) in Iranian Patients with Osteoporosis. Journal of Osteoporosis. ISSN 2090-8059

This list was generated on Thu May 8 18:44:10 2025 +0330.